Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Xytis Pharmaceuticals Ltd.

This article was originally published in Start Up

  • Laura A. Rush

Executive Summary

Xytis Pharmaceuticals Ltd., focused on in-licensing and developing late-stage CNS drug candidates, is taking a unique approach to treating schizophrenia by developing a drug that targets the NMDA receptor complex.

You may also be interested in...



Treating Traumatic Brain Injury

Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?

Treating Traumatic Brain Injury

Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?

Building a Better Drug for Schizophrenia

Start-ups in pursuit of novel targets are capturing the attention of venture capitalists.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical
Latest Headlines

China VBP, Localization And Other Strategies - How Far And Which Way?

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

With One Launch Under Way, SpringWorks Ramps Up For A Second

Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar

See All
UsernamePublicRestriction

Register

SC091092

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By